Evidence method
Level · gp.fundamentals.capex_revenue_ratio
4.91% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
CTKB · Mar 31, 2026
Cytek Biosciences, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001628280-26-032293General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-6.20% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
6.46% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
112.82% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
48.16% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-41.83% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
21.76% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
11.01% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History21 statesSelf-history eligible
Sep 30, 20210/7 normalizedLevel 3Dec 31, 20210/7 normalizedLevel 3Mar 31, 20220/7 normalizedLevel 3Jun 30, 20220/8 normalizedLevel 3Sep 30, 20220/8 normalizedLevel 3Dec 31, 20220/8 normalizedLevel 3Mar 31, 20230/8 normalizedLevel 3Jun 30, 20235/8 normalizedLevel 3Sep 30, 20237/8 normalizedLevel 3Dec 31, 20237/8 normalizedLevel 3Mar 31, 20247/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/8 normalizedLevel 3Mar 31, 20258/8 normalizedLevel 3Jun 30, 20258/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Mar 31, 20268/8 normalizedLevel 3Jun 30, 20268/8 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 2.03%
- Current
- 4.91%
- Delta
- 2.89%
- Previous
- -2.33%
- Current
- -6.20%
- Delta
- -3.87%
- Previous
- 0.52%
- Current
- 6.46%
- Delta
- 5.94%
- Previous
- 24.03%
- Current
- 112.82%
- Delta
- 88.78%
- Previous
- 51.84%
- Current
- 48.16%
- Delta
- -3.69%
- Previous
- -20.04%
- Current
- -41.83%
- Delta
- -21.79%
- Previous
- 18.10%
- Current
- 21.76%
- Delta
- 3.66%
- Previous
- 12.20%
- Current
- 11.01%
- Delta
- -1.19%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Analogous To · CTKB state analogue 2 →Transitioned To · CTKB Fundamental State →Transitioned To · CTKB CAPEX_INTENSITY_INCREASED →Transitioned To · CTKB CASH_GENERATION_DECREASED →Transitioned To · CTKB GROWTH_INCREASED →Transitioned To · CTKB INVENTORY_PRESSURE_INCREASED →Transitioned To · CTKB MARGIN_DECREASED →Transitioned To · CTKB PROFITABILITY_DECREASED →Transitioned To · CTKB R_AND_D_INTENSITY_INCREASED →Transitioned To · CTKB SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.